Y-J Kim

Keratitis, ichthyosis and deafness syndrome with development of multiple hair follicle tumours.

Summary We report multiple occurrences of various kinds of tumours that originate from hair follicles in a patient diagnosed with KID (keratitis, ichthyosis, deafness) syndrome. These tumours are diagnosed as: (i) trichilemmal cysts in early lesions; (ii) proliferating trichilemmal tumours in moderate duration lesions; and (iii) malignant proliferating trichilemmal tumours in advanced lesions that are thought to progress from benign trichilemmal lesions. This three‐step process raises the hypothesis of a multihit model that could account for the frequent development of tumours in KID patients.

ANALYSIS OF MOVING AND FIXED AUTOBLOCK SYSTEMS FOR KOREAN HIGH SPEED RAILWAY

Railway authorities of several countries are studying a new autoblock system: the Moving Autoblock System (MAS). As the efficiency of MAS has already been verified through various studies, especially in a line with different types of traveling trains, MAS is adapted as an autoblock system in some countries to increase their line capacity. The efficiencies of MAS and a Fixed Autoblock System (FAS) for a Korean high-speed line with two different train models are analyzed by computer simulation. The results show that MAS is more efficient than FAS in the line capacity. This paper considers only the braking distance of two trains. All other factors will be considered in the next phase.

Anti-heparan sulfate antibody and functional loss of glomerular heparan sulfate proteoglycans in lupus nephritis:

Background The purpose of this study was to evaluate the features of heparan sulfate proteoglycans (HSPGs) as agrins of the glomerular basement membrane (GBM) and circulating anti–heparan sulfate (HS) antibodies in lupus nephritis, comparing titers among the following groups: lupus nephritis (LN), non-renal lupus, non-lupus nephritis, and healthy controls. Methods The stage of nephritis was determined based on the kidney biopsy. Alcian blue staining and immunohistochemical (IHC) staining for agrin were performed for histological evaluation of GBM HSPGs in normal glomeruli, non-lupus membranous glomerulonephritis (MGN), and lupus MGN. The results were used for measurement of the serum anti-HS antibody titers using an enzyme-linked immunosorbent assay (ELISA) in the following groups: 38 healthy controls, 38 non-lupus nephritis, 37 non-renal lupus, and 38 LN. Results Glomerulus HSPGs were stained bluish-green along the GBM with Alcian blue. However, IHC staining against agrin was almost completely negative in the lupus MGN group compared with the normal and non-lupus MGN groups, which showed brown staining of GBM. A higher level of anti-HS IgG was detected in LN compared with other groups, respectively. Higher titers were associated with the presence of SLE and nephritis. A higher degree of proteinuria normalized to glomerular filtration rate (eGFR) was observed in association with higher anti-HS antibody titers in LN. Conclusion This study demonstrated a functional loss of GBM HSPGs and higher levels of circulating anti-HS antibodies as a characteristic feature of lupus nephritis, suggesting their involvement in the pathogenesis of lupus nephritis and proteinuria.

Design of On-Board Computer System for Korean High-Speed Train

현재 KERI의 고속전철 T.F.T.는 최고속도 350kph를 목표로 하는 한국형 고속전철 개발과제에 참여하고 있다. KERI의 연구분야는 전기시스템 엔지니어링으로, 열차의 전기 및 기계시스템의 진단 및 제어를 수행하는 자상컴퓨터시스템의 엔지니어링 설계를 포함하고 있다. 본 설계는 승객의 안전과 제작, 운전, 유지보수 단계에서의 경제성 확보라는 측면에 시스템 엔지니어링 개념을 두고 있다. 본 논문에서는 한국현 고속전철(KHST)의 안전성과 신뢰성을 책임지는 차상컴퓨터시스템의 엔지니어링 설계안을 제시한다. 본 설계안은 네트웍을 통한 분산처리시스템에 초점을 맞추고 있다.

ANTI-SLIP CONTROL SYSTEM OF KOREAN HIGH-SPEED TRAIN

This paper describes the antislip control system for the Korean High Speed Train with induction motor drive. To use a maximum adhesive effort and to improve tractive performance, adhesion characteristics of a high-speed train are analyzed, and an antislip control system is designed. A novel antislip control scheme is proposed for a propulsion system with an induction motor by vector control. In order to verify the control system, a down-scaled antislip control simulator is set up; and running tests with this simulator are performed.

Abstract P4-13-19: Poziotinib, an oral, irreversible pan-HER inhibitor, demonstrates promising clinical activity in metastatic HER2 positive breast cancer patients

Background: Poziotinib is a novel, oral, irreversible pan-HER inhibitor that has been studied in two completed Phase 1 clinical trials in patients with advanced solid tumors (HM-PHI-101; HM-PHI-102) and is currently being studied in several Phase 2 clinical trials. Preclinical studies have shown poziotinib to be more potent in vitro than other EGFR- and HER2-directed tyrosine kinase inhibitors. This study collates the clinical experience of poziotinib in patients with advanced HER2 positive breast cancer from the two completed Phase 1 trials. Results: The maximum tolerated dose (MTD) and safety of poziotinib were evaluated in HM-PHI-101 (once daily, Day 1-14 q3 weeks) and in HM-PHI-102 (continuous dosing). The Dose Limiting Toxicity (DLT) was diarrhea in both studies. Anti-diarrheal medicine was allowed, but prophylactic anti-diarrheal therapy was not used. The most frequently reported Grade 3 AE was diarrhea (40%). The MTD for intermittent dosing of poziotinib was 24 mg and the MTD for continuous dosing was 16 mg. The Dose Limiting Toxicity (DLT) was diarrhea in both studies. Anti-diarrheal medicine was allowed, but prophylactic anti-diarrheal therapy was not used. In total, 10 patients with HER2 positive metastatic breast cancer were treated in the two trials (median age 56.5, range 30-69). These patients were heavily pretreated (median number of previous treatment regimens 5, range 3-9), and all patients had failed treatment with both trastuzumab and lapatinib. The Overall Response Rate (ORR) in these breast cancer patients was 60% and Clinical Benefit Rate (CBR) was 80%. The median duration of response was 32.5 weeks (range 18 - 56 weeks). Two patients in the early dose cohorts of 1 or 2mg had progressive disease. The median progression free survival (PFS) was 28 weeks (6, 6, 12, 17, 25, 31, 37, 49, 57, and 98 weeks). Conclusions: Poziotinib showed very promising clinical activity in Phase 1 patients with metastatic HER2 positive breast cancer, who had been heavily pretreated and failed two prior HER2-directed therapies. The ORR in this patient population was 60% and the CBR was 80% in these two early dose finding studies. The AEs observed in these studies was consistent with other pan-HER and EGFR inhibitors. While the majority of DLT cases involves diarrhea, toxicity of other adverse events was relatively tolerable. An intermittent dosing schedule seemed appropriate for poziotinib. Multiple Phase 2 studies with poziotinib are ongoing in patients with breast cancer and other solid tumors. Citation Format: Im S-A, Kim J-H, Lee K-H, Kim SH, Oh D-Y, Kim Y-J, Han S-W, Kim T-Y, Kim T-Y, Jung J, Bang Y-J. Poziotinib, an oral, irreversible pan-HER inhibitor, demonstrates promising clinical activity in metastatic HER2 positive breast cancer patients. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-13-19.

Predictors of Revisit and Admission after Discharge from an Emergency Department in Acute Pyelonephritis

Introduction The aim of this study is to construct clinical prediction models to predict emergency department (ED) return visit following initial discharge for acute pyelonephritis (APN) and the need for hospital re-admission upon ED return visits. Method A retrospective analysis included 1250 discharged women with APN. Independent risk factors for revisit and subsequent admission after revisit were determined by multivariate analysis, and a prediction model for revisit and subsequent admission after revisit was constructed. Results Independent risk factors for revisit were nausea (2 points), age ≥ 65 years (2 points), C-reactive protein >20 mg/dL (2 points), serum albumin <3.3 g/dL (3 points) and urine white blood cell count ≥ 30/high power field (2 points). Re-visit risk scores were categorised to five groups and the re-visit rate was 5.4%, 8.6%, 12.2%, 19.1% and 43.8%, respectively, showing an area under curve (AUC) of 0.62. Risk factors for subsequent admission after revisit were vomiting (1 point), hypertension (2 points), serum creatinine <1.5 mg/dL (2 points), C-reactive protein >20 mg/dL (2 points) and serum albumin <3.3 g/dL (4 points). The subsequent admission after revisit risk scores were classified to three groups and subsequent admission after revisit rate was 3.5%, 15.0%, and 38.2%, respectively. Conclusion The developed model can identify a group of patients at high risk for a return visit and for requiring subsequent hospital admission, and might be used to improve initial disposition decision and discharge instructions. (Hong Kong j.emerg. med. 2015;22:154-162)

Speed Control System Of Induction Motor With Fuzzy-sliding Mode Controller For Traction Applications

This paper presents application of sliding mode control for improving the dynamic response of an induction motor based speed control system. It provides useful features such as fast response, good transient performance, insensitivity to variations in plant parameters and external disturbance. A new fuzzy-sliding mode controller for a sensorless vector controlled induction motor servo system is presented to attempt to eliminate the chattering problem for traction applications. DSP-based implementation of speed control system is employed. Experimental results are given using a propulsion system simulator. The performance of the drive is shown to be practically free from the chattering problem.

Traction system combined test of the KHST (Korean High Speed Train)

This paper introduces the combined test results of the traction system for KHST(Korean High Speed Train: hereafter refer to KHST). The main purpose of this combined test is to verify the performance of the traction system that is designed to operate up to maximum 350kmih speed. Combined test system consists of a traction transformer, two AC-DC PWM converters, a PWM Inverter, two traction motors and flywheel system. Flywheel system represents equivalent model of the train inertia. Also traction control system and MASCON Interfaces are included. Various kinds of experiments are performed to prove total traction system performance and detailed waveforms are described.

Sensorless control methods for variable speed drives with induction motor used in traction application

This paper contains several proposed methods for sensorless control of the rotor field-oriented induction motor. These include: speed estimators, rotor slot ripple speed estimators, Model Reference Adaptive Systems, and Luenberger speed observer. The validity of the proposed methods are verified by simulation, with the sensorless control also being tested on the propulsion system simulator used for the development of the Korean High-Speed Railway Train.